Casa Physicians Alliance News
Sanofi: Influenza in the Senior Population- Prevention
Fluzone High-Dose vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus contained in the vaccine.
Fluzone High-Dose vaccine is approved for use in persons 65 years of age and older. We are pleased to invite you to take part in an on-demand webcast on influenza immunization titledInfluenza in the Senior Population: Sharing the Latest Evidence on Disease Prevention.
This non-CME webcast program, focusing on the impact of influenza disease in seniors, will feature a presentation by Marvin J. Bittner, MD, Associate Professor of Internal Medicine, Medical Microbiology, and Immunology at Creighton University School of Medicine in Omaha, Nebraska. Dr. Bittner will share key data from a clinical trial in which Fluzone ® High-Dose (Influenza Vaccine) was significantly more effective than Fluzone vaccine in preventing laboratory-confirmed influenza in people 65 years of age and older.
Influenza in the Senior Population: Sharing the Latest Evidence on Disease Prevention is now available on demand through May 2016.
For additional details about this program, as well as information on how to participate, please refer to the attachment.
To register, please click on the link below.
We thank you for your consideration and your interest in disease prevention and look forward to your participation.
IMPORTANT SAFETY INFORMATION
The most common local and systemic adverse reactions to Fluzone High-Dose vaccine include pain, erythema, and swelling at the injection site; myalgia, malaise, headache, and fever. Other adverse reactions may occur. Fluzone High-Dose vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.
If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose vaccine should be based on careful consideration of the potential benefits and risks. Vaccination with Fluzone High-Dose vaccine may not protect all individuals.
Before administering Fluzone High-Dose vaccine, please click here for full Prescribing Information.
In accordance with Sanofi Pasteur’s policies and the PhRMA Code on Interactions with Healthcare Professionals, attendance at this educational program is limited to health care professionals.
Value transfers to licensed health care professionals by pharmaceutical companies may need to be reported according to certain state laws, as well as Federal Sunshine Act Provisions.
This is a non-CME educational event. CME credit will not be offered for this program.
Fluzone High-Dose vaccine is manufactured and distributed by Sanofi Pasteur Inc.
Posted by Shari Smith on 6th January, 2016 | Comments | Trackbacks
Tags: CASA Physicians Alliance, Sanofi Flu Partners Program, Influenza Vaccine, Sanofi Fluzone, Seasonal Flu, Influenza, Sanofi Pasteur Flu Vaccine, Group Purchasing Organization, Healthcare Professional, Vaccine Group Purchasing Program, Adult Vaccine, Savings on Adult Vaccines, Quadrivalent Influenza Vaccine, Quadrivalent Flu Vaccine, Schedule your Flu Shot, Discount Sanofi Vaccines, Vaccine Savings
The trackback URL for this page is http://www.casaalliance.net/trackback?post=32408761
There are no trackbacks for this post
There are no comments for this post
Post a Comment
HTML is not allowed in comments, http://... will be automatically linked.